3,5,3′‐TRHODOTHYROACETIC ACID MINIMIZES THE PITUITARY THYROTROPHIN SECRETION IN PATIENTS ON LEVO‐THYROXINE THERAPY AFTER ABLATIVE THERAPY FOR DIFFERENTIATED THYROID CARCINOMA

Authors:
Publisher website
Google Scholar
Abstract
The aim of this study was to examine the influence of 3,5,3′‐triiodothyroacetic acid (TRIAC) on serum thyrotrophin (TSH) concentration in 25 patients on levo‐thyroxine (L‐T4) therapy after ablative therapy for differentiated thyroid carcinoma. The daily L‐T4 intake amounted to 2.6 ± 0.7 μg/kg body weight (± SD). Serum TSH concentration was determined by means of a sensitive radioimmunometric method (lower detection limit 003 mU/l). The median (x̄) basal TSH concentration under L‐T4 amounted to 0.11 mU/l (range PP<0.0001). A blunted TSH‐response to TRH occurred in 8.7% prior to and in 52% of the patients during TRIAC medication. Side effects such as nervousness, cardiac arrhythmia or tachycardia under supplementary TRIAC (500 μg daily) were observed in four patients. The conclusion is that the supplementary medication of 500 μg TRIAC daily in euthyroid patients on L‐T4 medication after thyroid gland ablation for differentiated thyroid cancer is an effective means to minimize serum‐TSH concentration.

This publication has 15 references indexed in Scilit: